Viatris Inc
VIA
Company Profile
Business description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Contact
1000 Mylan Boulevard
CanonsburgPA15317
USAT: +1 724 514-1800
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
30,000
Stocks News & Analysis
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,977.20 | 48.20 | -0.53% |
| CAC 40 | 8,047.69 | 78.27 | 0.98% |
| DAX 40 | 25,981.09 | 162.88 | 0.63% |
| Dow JONES (US) | 52,128.70 | 358.39 | 0.69% |
| FTSE 100 | 10,761.33 | 31.55 | 0.29% |
| HKSE | 23,393.32 | 98.90 | 0.42% |
| NASDAQ | 25,322.63 | 114.37 | -0.45% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,698.63 | 98.37 | -0.71% |
| S&P 500 | 7,572.64 | 7.43 | -0.10% |
| S&P/ASX 200 | 8,856.50 | 51.60 | -0.58% |
| SSE Composite Index | 3,638.03 | 39.01 | 1.08% |